Gilead Stock News

HOOKIPA (HOOK) shares are 45% higher in after-hours trading after it amended an agreement with Gilead (GILD) for the development of an arenaviral immunotherapy for HIV.

HOOKIPA to develop arenaviral-based therapeutic for HIV through Phase 1b clinical trial completion; Gilead has exclusive rights for further program development thereafter Financial terms include $15 million initiation fee and $35 million equity commitment NEW YORK and VIENNA, Austria, Feb. 15, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK , ‘HOOKIPA'')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced it has entered into an amended and restated collaboration and license agreement with Gilead to advance the development of a novel arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV). In April 2018, Gilead licensed exclusive rights to HOOKIPA''s versatile arenaviral platform to develop immunotherapies for HIV and hepatitis B virus (HBV). Under those terms, the companies agreed to collaborate through a joint research phase, after which time Gilead had rights for further development.

How will the cost of a settlement affect Gilead's profits over the foreseeable future?

How will the cost of a settlement affect Gilead''s profits over the foreseeable future?

Which ETFs Should Investors Be Watching Now? Our Favorite Is The IBB

WASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Antibody Drug Conjugates (ADCS) Market finds that granted accelerated approval for biologics license applications is expediting market growth. Primarily driven by favourable effective biopharmaceutical medications developed as a targeted therapy for cancer therapy, the total global Antibody Drug Conjugates (ADCS) Market is estimated to reach USD 13.17 Billion by 2028. The Market valued at a revenue of USD 4.24 Billion in 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 18.9%. Furthermore, the rising benefit of Antibody Drug Conjugates (ADCS) as the unharmed healthy cells enable patients to recover quickly, thus growth of the Global Antibody Drug Conjugates (ADCS) Market, states Vantage Market Research, in a report, titled " Antibody Drug Conjugates (ADCS) Market by Application (Breast Cancer, Urothelial Cancer & Bladder Cancer, Other Cancer, Blood Cancer), by Technology (Cleavable Linker, Non-Cleavable Linker, Linkerless), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.

Gilead Sciences Inc (NASDAQ: GILD ) announced new data from an interim analysis of its ongoing, Phase 2/3 study of Veklury (remdesivir) in pediatric patients hospitalized with COVID-19. The data will be presented at the 29th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2022). The latest data demonstrate that Veklury was generally well-tolerated among Full story available on Benzinga.com

President Joe Biden said it's "probably premature" for states to drop their indoor face mask requirements, as Nevada became the latest to scrap it at most places including its casinos.

Gilead Sciences Inc (NASDAQ: GILD) announced new data from an interim analysis of its ongoing, Phase 2/3 study of Veklury (remdesivir) in pediatric patients hospitalized with COVID-19. The data wil

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate

Merck is 90% focused on human drugs and is highly diversified globally. See why I think MRK stock could deliver 24% annual returns over the next two years.

How a drug used to treat parasites for decades became the hot and controversial drug of the pandemic

If Gilead has bad news on magrolimab, it could ripple throughout the industry.

If Gilead has bad news on magrolimab, it could ripple throughout the industry.